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Human hookworms are parasitic nematodes infecting about 700 million individuals, 
largely in tropical regions of the 
world [1]. In endemic areas, most 
infected people carry a mixed worm 
burden, including Ascaris lumbricoides 
(roundworms), Trichuris trichuria 
(whipworms), and Ancylostoma 
duodenale and/or Necator americanus 
(both hookworms). Of these soil-
transmitted helminths, hookworms are 
the most pathogenic because of their 
propensity to feed on blood, resulting 
in anaemia, particularly in those with 
low iron reserves such as children and 
women of reproductive age. 
The Pathogenesis of Hookworm 
Infection
Hookworms’ blood-feeding 
(hematophagous) habits cause 
pathology in humans and animals. 
The worms attach to the wall of the 
small intestine using their mouthparts 
and feed on blood from ruptured 
capillaries. Each female worm is 
estimated to ingest a minimal 0.1 ml 
of blood per day. However, actual 
blood loss can be signifi cantly greater; 
the worms change their feeding sites 
several times a day, and the secretion of 
anti-coagulants means that the vacated 
sites continue to bleed, contributing 
greatly to blood loss.
Hookworms do not kill, but they can 
cause subclinical disease, most notably 
anaemia and impaired physical and 
cognitive development in children. 
As hookworm infection is associated 
with low socioeconomic status, it adds 
signifi cantly to the burden of disease in 
such areas [1].
Natural Infection Elicits Poor 
Immunity 
Hookworms have a simple life cycle in 
which the third-stage larvae (L3) infect 
humans, generally by skin penetration, 
although some species are also infective 
via oral ingestion. The parasites enter 
the bloodstream and migrate to the 
lungs; from there, they are coughed 
and swallowed to the small intestine 
(Figure 1). The adult parasites mature 
in the intestine, and following mating, 
the female worm produces many 
thousands of eggs that pass out in the 
faeces and develop on the ground to 
infective L3.
Hookworms can be treated 
using anthelmintic drugs such as 
albendazole, but treated people soon 
become reinfected. Additionally, recent 
epidemiological studies from China 
and Brazil show the highest worm 
burden and the highest prevalence of 
infection in the elderly [2], contrasting 
with the intensity/prevalence curves for 
other soil-transmitted helminths, which 
typically peak in mid-to-late childhood. 
These data suggest that under natural 
conditions of exposure, little immunity 
is evoked. Given this immuno-
epidemiological picture, developing a 
vaccine is a signifi cant challenge. 
The Search for a Vaccine
Recent studies suggest that the 
hematophagous lifestyle of hookworms 
may prove their downfall. Hookworms 
are armed with an array of molecules 
that are essential for blood feeding and 
digestion; these include anticoagulants 
and a variety of proteases that digest 
haemoglobin (Hb) and other serum 
proteins. In a new article in PLoS 
Medicine, Loukas et al. [3] now 
describe a vaccination schedule 
using one such protease—an aspartic 
haemoglobinase—from the hookworm 
Ancylostoma caninum (Ac-APR-1). In 
their study, the schedule protected 
against blood loss in an animal model 
of hookworm infection.
As with other parasitic nematodes, 
hookworms are complex multicellular 
organisms that have evolved an array 
of mechanisms for suppressing or 
avoiding host immune responses. The 
only commercially available vaccine 
against a parasitic nematode is Huskvac 
(an oral lungworm vaccine for calves), 
a preparation of radiation-attenuated 
L3 of Dictyocaulus viviparus, which 
protects against parasitic bronchitis 
[4]. In the 1960s, a similar approach 
was adopted to controlling hookworm 
infection in dogs using irradiated L3 
of A. caninum [5]. While this vaccine 
was effi cacious, it was a commercial 
failure. However, these older vaccines 
established the principle that protective 
immunity can be elicited. The 
challenge now is to identify protective 
antigens and present them to the 
immune system in an appropriate 
manner. 
Proteases as Potential Vaccine 
Candidates 
Hookworms express a range of 
proteases, including cysteine, aspartic, 
and metallo-proteases, several of which 
have been characterised in detail. 
These enzymes are localised to the 
brush border of the worm intestine and 
have been shown to function in a multi-
enzyme cascade to digest Hb and other 
serum proteins [6]. Some of these 
molecules show an exquisite specifi city; 
for example, Na-APR-2, an aspartic 
protease from N. americanus, cleaves Hb 
from the permissive host (human) with 
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twice the effi ciency of Hb from a non-
permissive host (dog) [7]. 
These gut-associated molecules of the 
parasite have been the focus of recent 
interest as potential vaccine candidates. 
The rationale behind this approach 
is that the induction of antibodies to 
molecules that function in parasite 
feeding will neutralise their activity 
and effectively “starve” the worm. A 
similar approach has previously been 
trialled against nematode parasites of 
livestock such as Haemonchus contortus 
[8], and some important lessons 
have been learned. One of these is 
the requirement for expression of 
recombinant molecules in a eukaryotic 
system [9]. In general, bacterial-
expressed antigens do not stimulate 
protection, presumably because they 
are improperly folded and/or modifi ed 
and catalytically inactive. 
Under the auspices of the Human 
Hookworm Vaccine Initiative and the 
Sabin Vaccine Institute (http:⁄⁄www.
sabin.org/hookworm.htm), which 
supported Loukas and colleagues’ 
study [3], the drive to develop 
a hookworm vaccine has gained 
signifi cant momentum. A number of 
candidate antigens have been tested in 
the A. caninum dog model with varying 
degrees of success. Ideally, vaccination 
would protect against infection with 
L3. The same team of researchers have 
previously identifi ed one such secreted 
molecule of the L3 of N. americanus, Na-
ASP-2 (for abundant secreted protein-
2), and have shown it to partially 
protect dogs against infection [10]. 
Phase 1 safety trials are now underway 
with this antigen. 
Other candidate molecules are the 
cysteine and aspartic haemoglobinases 
from the adult worm. In another study 
by Loukas and colleagues, vaccination 
with a catalytically active cathepsin-
B-like protease from A. caninum (Ac-
CP-2) produced in the yeast Pischia 
pastoris resulted in worms that were 
stunted and produced fewer eggs 
but did not produce a reduction in 
number of worms or protect against 
anaemia [11]. The current study 
from the same group tested an active 
aspartic haemoglobinase (Ac-APR-
1) in the same model [3]. A modest 
reduction in worm burden was 
observed in immunised animals, but a 
highly signifi cant reduction in worm 
fecundity was observed (up to 85% 
reduction in mean egg output between 
vaccinated and adjuvant-only controls), 
emphasising the nutritional demand 
of the parasite for egg laying and 
presumably refl ecting an accumulation 
of neutralising antibodies. Most 
importantly, four of fi ve vaccinated 
animals showed a reduction in Hb 
loss. Thus Ac-APR-1 could represent 
a pathology-limiting component of 
a future multivalent vaccine [3]. In 
addition, by restricting worm fecundity 
it would, in essence, also act as a 
“transmission blocking” vaccine.
The Challenges Ahead
Despite these achievements, signifi cant 
challenges remain, such as the 
selection of appropriate adjuvants 
for use in humans, the production 
of the vaccine at low cost and high 
yield, its distribution in the tropics, 
and the possible requirement to de-
worm individuals prior to vaccination. 
However, the Human Hookworm 
Vaccine Initiative is progressing 
on many of these fronts and is an 
excellent example of what can be 
achieved with proper funding and 
good collaborations. It has the 
potential to become a 21st-century 
paradigm for a control programme 
aimed at a neglected tropical disease 
and should also provide renewed 
impetus to control programmes aimed 
at vaccine development against other 
hematophagous helminths of humans 
and domestic animals. 
Finally, it is somewhat ironic to 
note that as attempts are made to 
eradicate worm infection in tropical 
regions of the world, worms are being 
used in the developed countries to 
regulate pathogenic proinfl ammatory 
immune responses. For example, 
patients with ulcerative colitis have 
shown an encouraging amelioration of 
pathology following infection with the 
pig whipworm Trichuris suis [12]. These 
studies demonstrate the capacity of 
helminth parasites to induce regulatory 
DOI: 10.1371/journal.pmed.0020327.g001
Figure 1. Life Cycle of the Human Hookworm N. americanus
(Illustration: Sapna Khandwala, reproduced from [13]) 
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immune networks in their hosts, 
and they emphasise the scale of the 
challenge facing the development of 
vaccines against worms. 
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